Peter Radovich Mirum Pharmaceuticals, Inc. (MIRM) insider trading activity

MIRM Quotes by TradingView

Peter Radovich is PRESIDENT AND COO of Mirum Pharmaceuticals, Inc.. Currently has a direct ownership of 18,672 shares of MIRM, which is worth approximately $860,405. The most recent transaction as insider was on Mar 17, 2025, when has been sold 7,879 shares (Common Stock) at a price of $44.21 per share, resulting in proceeds of $348,330. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 18.7K
35.64% 3M change
35.64% 12M change
Total Value Held $860,405

Peter Radovich Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 17 2025
SELL
Open market or private sale
$348,330 $44.21 p/Share
7,879 Reduced 29.67%
18,672 Common Stock
Mar 15 2025
BUY
Exercise of conversion of derivative security
-
14,440 Added 35.23%
26,551 Common Stock
Mar 04 2025
SELL
Open market or private sale
$678,051 $45.66 p/Share
14,850 Reduced 55.08%
12,111 Common Stock
Feb 03 2025
SELL
Open market or private sale
$126,673 $48.22 p/Share
2,627 Reduced 8.88%
26,961 Common Stock
Jan 24 2025
SELL
Open market or private sale
$152,241 $47.92 p/Share
3,177 Reduced 9.7%
29,588 Common Stock
Jan 23 2025
BUY
Exercise of conversion of derivative security
-
5,750 Added 14.93%
32,765 Common Stock
Jan 07 2025
SELL
Open market or private sale
$85,554 $42.82 p/Share
1,998 Reduced 6.89%
27,015 Common Stock
Mar 25 2024
SELL
Open market or private sale
$111,017 $25.8 p/Share
4,303 Reduced 12.92%
29,013 Common Stock
Feb 02 2024
SELL
Open market or private sale
$46,880 $26.19 p/Share
1,790 Reduced 4.91%
34,695 Common Stock
Jan 08 2024
SELL
Open market or private sale
$39,466 $28.03 p/Share
1,408 Reduced 3.72%
36,485 Common Stock
Nov 10 2023
BUY
Grant, award, or other acquisition
$4,859 $22.29 p/Share
218 Added 0.57%
37,893 Common Stock
Jul 03 2023
SELL
Open market or private sale
$36,551 $25.65 p/Share
1,425 Reduced 3.64%
37,675 Common Stock
May 10 2023
BUY
Grant, award, or other acquisition
$16,378 $16.92 p/Share
968 Added 2.42%
39,100 Common Stock
Jan 31 2023
BUY
Grant, award, or other acquisition
-
14,440 Added 27.47%
38,132 Common Stock
Jan 09 2023
SELL
Open market or private sale
$28,434 $20.62 p/Share
1,379 Reduced 3.97%
33,316 Common Stock
Nov 10 2022
BUY
Grant, award, or other acquisition
$4,978 $17.05 p/Share
292 Added 1.22%
23,692 Common Stock
May 10 2022
BUY
Grant, award, or other acquisition
$15,863 $13.57 p/Share
1,169 Added 4.76%
23,400 Common Stock
Jan 06 2022
BUY
Grant, award, or other acquisition
-
10,000 Added 31.03%
22,231 Common Stock
Nov 10 2021
BUY
Grant, award, or other acquisition
$12,952 $13.52 p/Share
958 Added 7.26%
12,231 Common Stock
Oct 01 2021
SELL
Open market or private sale
$26,271 $19.26 p/Share
1,364 Reduced 10.79%
11,273 Common Stock
Sep 29 2021
BUY
Grant, award, or other acquisition
-
8,125 Added 39.13%
12,637 Common Stock
May 10 2021
BUY
Grant, award, or other acquisition
$14,708 $14.62 p/Share
1,006 Added 18.23%
4,512 Common Stock
Nov 10 2020
BUY
Grant, award, or other acquisition
$13,147 $15.27 p/Share
861 Added 19.72%
3,506 Common Stock

Also insider at

RAIN
Rain Therapeutics Inc. Healthcare
Director
PR

Peter Radovich

PRESIDENT AND COO
Newark, CA

Track Institutional and Insider Activities on MIRM

Follow Mirum Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MIRM shares.

Notify only if

Insider Trading

Get notified when an Mirum Pharmaceuticals, Inc. insider buys or sells MIRM shares.

Notify only if

News

Receive news related to Mirum Pharmaceuticals, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on MIRM